皮肤T细胞淋巴瘤治疗格局、疾病负担与未满足需求
皮肤T细胞淋巴瘤呈慢性复发性病程,以蕈样肉芽肿和Sézary综合征最常见,可致脱发、瘙痒和疼痛,影响健康相关生活质量。治疗目标为减轻症状和防止进展,但推荐多基于低级别证据,获批药物地区差异大,现有治疗罕见持久缓解且易失效,早期用皮肤导向治疗、晚期或无效者需系统治疗,存在对高效安全疗法的未满足需求。
要点
- CTCL慢性复发,常见亚型为蕈样肉芽肿和Sézary综合征,显著影响生活质量。
- 治疗推荐常基于低级别证据,获批药物因国家/地区而异。
- 现有治疗罕见持久缓解且易失效,需多次更换方案,存在未满足需求。
核心结论
- CTCL治疗推荐多基于低级别证据,现有疗法罕见持久缓解,存在对高效安全疗法的未满足需求。
研究设计与样本
- 综述,汇总当前治疗指南、在研与获批治疗、CTCL对健康相关生活质量的影响及瘙痒治疗。
主要发现
- CTCL呈慢性复发性病程,最常见亚型为蕈样肉芽肿和Sézary综合征。
- 疾病引起可见皮肤改变,并可致脱发、瘙痒和疼痛,影响健康相关生活质量。
- 现有治疗罕见持久缓解并最终疗效下降,患者常需多次更换治疗。
- 系统治疗可能用于对皮肤导向治疗无反应的早期病变或晚期病变,但副作用显著或无法耐受。
关键数值与推荐
- 皮肤导向治疗为早期CTCL一线治疗;系统治疗用于SDT无反应的早期病变或晚期病变。
- 治疗推荐常基于低级别证据,因缺乏设计良好的随机临床试验和治疗指南。
- 获批药物在不同国家和地区差异很大。
临床怎么用
- 早期CTCL优先皮肤导向治疗,无效或晚期考虑系统治疗并监测副作用与耐受性。
- 因现有疗法易失效,需动态评估疗效并准备多线治疗转换。
局限性
- 治疗推荐多基于低级别证据,缺乏设计良好的随机临床试验和治疗指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous T-cell lymphomas (CTCLs) have a chronic, relapsing course, and the most common subtypes are mycosis fungoides and Sézary syndrome. The disease causes visible skin alterations and can also cause alopecia, pruritus and pain, all of which can impact patients' health-related quality of life (HRQoL). The goal of treatment is to reduce symptoms and prevent disease progression. However, treatment recommendations are often based on low levels of evidence due to the lack of well-designed randomised clinical trials and treatment guidelines, and approved drugs vary considerably across different countries and regions. Currently, available treatments rarely lead to durable remissions and eventually become less effective, meaning patients often require multiple therapy changes. Skin-directed therapies (SDTs) are first-line treatments for early-stage CTCL, whereas systemic therapies may be needed for early-stage disease that does not respond to SDT or for advanced-stage disease. However, patients can experience significant side-effects with these treatments or may be unable to tolerate them. Hence, there is an unmet need for effective therapies with good safety profiles for the treatment of early- and late-stage CTCL. Here, we review current treatment guidelines, investigational and approved treatments, the impact of CTCL on patients' HRQoL, and the treatment of pruritus.
引用
- Scarisbrick JJ, Bagot M, Ortiz-Romero PL, et al. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol. 2020. PMID: 33095448. doi:10.1111/bjh.17117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。